## VIRAL RESPIRATORY TRACT INFECTION:

## 1- RHINOVIRUS:

• Nonenveloped, Icosahedral, +Sense single strand RNA virus

• 3 species (A, B & C) based on sequence analyses.

• enter through the **upper respiratory tract.** 

 $33^{\circ}C$ 

•Replication: epithelium of the nasal mucosa

• Histopathologic changes: submucosa + epithelium (edema and mild cellular infiltration)

• There's a direct correlation between the amount of virus in secretions and the severity of illness.

The incubation period: 2 to 4 days. /Acute illness: 7 days / Nonproductive: 2–3 weeks.

- Cause **upper respiratory tract infections**, common cold syndrome.
- half of acute asthma exacerbations.
- •Symptoms in Adults: sneezing, nasal obstruction, nasal discharge, and sore throat. headache, mild cough, malaise, and a **chilly sensation**. There is generally little or no fever. **Mucosal Changes:** The nasal and nasopharyngeal mucosa exhibit redness and swelling.
- •**SECONDARY BACTERIAL INFECTIONS:** acute otitis media, sinusitis, bronchitis, or pneumonitis, especially **in children.**

## 2- CORONAVIRUS:

- enveloped, +ss RNA, helical capsid
- The Coronaviridae contain six genera (Alphacoronavirus, Betacoronavirus, Gammacoronavirus, Deltacoronavirus, Bafinivirus, and Torovirus) .
- •Pathogenesis: Often displaying tropism for epithelial cells in the respiratory or gastrointestinal tract
- •In Vivo Infections: In vivo, coronavirus infections can either be disseminated, as seen with mouse hepatitis virus, or localized. In humans, coronavirus infections typically, though not always, remain limited to the upper respiratory tract.
- **Diseases: common cold**, **SARS**(2003→ was detected not only in the respiratory tract but also in other organs such as the kidney, liver, small intestine, and stool/ **COVID-19**), **MERS** (2012→ pneumonia and respiratory failure, with most fatalities occurring in patients with medical comorbidities. , originated in bats and became widespread in camels)

• **Diagnosis:** RT-PCR + (NAAT)

**SARS-CoV-2 and COVID-19**: Asymptomatic/ Common symptoms: fever, dry cough, shortness of breath, and fatigue. More specific: anosmia and dysgeusia.

Complications: (ARDS), hypercoagulability (including cryptogenic and/or ischemic stroke), shock, organ failure, and death.

Risk Factors: increasing age (strongest).

Divided into:

major: use (ICAM-1) as receptor

and

minor: bind (LDLR) family.

•**Transmission:** respiratory droplets and aerosols. entry occurs through the attachment of the viral spike protein to the **ACE2 receptor** on cell membranes.



- Immunity and Vaccination: Anti-spike protein antibodies confer immunity. Vaccination induces both humoral and cellular immunity.
- Treatment: supportive/ O2/ Dexamethasone, remdesivir, and IL-6 pathway inhibitors

#### 3- ADENOVIRUS:

- •Nonenveloped, ds DNA, Icosahedral capsid
- replication in oropharynx
- •**Typical Symptoms:** Common symptoms of respiratory diseases include cough, nasal congestion, fever, and sore throat.
- •Group C virus types 1, 2, and 5 -> respiratory diseases in infants and children.

types 3, 7, and 21 in 10–20% of childhood pneumonias.

•Infections with types 3, 4, and 7 -> in adolescents and adults.

MILITARY RECRUIT RESPIRATORY SYNDROME: fever, sore throat, nasal congestion, cough, and malaise, with the potential to progress to pneumonia/ Epidemics occur among young military recruits, particularly under conditions of fatigue, stress, and crowding/ Type 4 and 7 are type 3 may also contribute to the syndrome.

## *4-PARAINFLUENZA*:

✓ Reinfections

- •enveloped, -ss RNA, helical capsid
- Types 1 and 3 belong to the genus Respirovirus
- Types 2, 4 a and 4b belong to the genus **Rubulavirus**
- •replication in immunocompetent hosts is primarily limited to respiratory epithelia.



- •types 1 and 2, involving the larynx and upper trachea, leading to croup (laryngotracheobronchitis),bark-like cough
- •Deeper spread to the **lower** trachea and bronchi, causing pneumonia or bronchiolitis type 3, albeit at a lower frequency than observed with RSV.
- virus-specific IgE is associated with disease severity.

#### **Primary Infections in Young Children:**

- rhinitis and pharyngitis, often accompanied by fever and some bronchitis. Ranging from laryngotracheitis and croup (types 1 and 2) to bronchiolitis and pneumonia (type 3).
- Severe illness associated with type 3 -> in infants under 6 months
- croup or laryngotracheobronchitis is more likely in children aged 6 months to 18 months.
- type 4 typically does not cause serious disease
- •Common Complication: otitis media.

**Immunocompromised children and adults** -> severe parainfluenza virus infections.

Mortality rates after parainfluenza infection in bone marrow transplant recipients range from 10% to 20%.

# 5- RESPIRATORY SYNCYTIAL VIRUS:

- •enveloped, -ss RNA, helical capsid
- •leading cause of **lower respiratory tract illness** in <u>infants</u> and young children, particularly responsible for **bronchiolitis** and pneumonia in those under 1 year.
- is a significant cause of otitis media

- begins in epithelial cells of the nasopharynx.
- •incubation period: 3-5 days/ Viral shedding:1-3 weeks in infants and young children, while adults: 1-2 days.
- reinfections usually involve the upper respiratory tract.
- •Viral antigens can be identified in the upper respiratory tract and in shedding epithelial cells
- •Patients with impaired **cell-mediated immunity** may become persistently infected with RSV, shedding the virus for extended periods, even months
- •Progression -> rapid, potentially culminating in death. Mortality rate in normal infants is low / In the presence of preexisting diseases like congenital heart disease, mortality rates may be high.
- •Treatment: Supportive measures (removal of secretions and the administration of oxygen.)

Antiviral Medication - Ribavirin: of lower respiratory tract, aerosol form over 3-6 days /X Oral

#### Globulin and Monoclonal Antibodies (palivizumab)

•RSV vaccine is available for pregnant ladies

6- METAPNEUMOVIRUS: 2001/ all ages/ wide range of respiratory illnesses

•Detected using a molecular approach on clinical samples from children with respiratory illnesses but with negative test results for known respiratory viruses.

Done by: mariam gussay

